Foundayo vs Wegovy pill
Orforglipron (Foundayo) and oral semaglutide (Rybelsus, Wegovy pill). What the research says about each, side by side. Every row comes from the studies and drug labels in the last row. More on each: Orforglipron and Oral semaglutide.
| Orforglipron | Oral semaglutide | |
|---|---|---|
| Category | GLP-1 and metabolic | GLP-1 and metabolic |
| Evidence | Extensive clinical research | Extensive clinical research |
| FDA status | FDA-approved as Foundayo on April 1, 2026 for chronic weight management in adults. Taken once a day, with or without food: the label sets no wait before eating. | FDA-approved as Rybelsus (2019, type 2 diabetes) and as the Wegovy pill (December 2025, weight management and heart risk). The labels say: take it in the morning on an empty stomach with up to 4 oz of water, then wait at least 30 minutes before eating, drinking or taking other pills. |
| How it works | It binds the GLP-1 receptor and triggers the same effects as GLP-1 shots: more insulin when sugar is high, slower stomach emptying and less appetite. | It switches on GLP-1 receptors in the pancreas, gut and brain, like the shots: more insulin when blood sugar is high, a slower stomach and quieter hunger. The tablet dissolves in the stomach, so food, drinks or other pills taken too soon block most of the dose from getting in. |
| Half-life | About 29 to 49 hours, so it builds to a steady level after about a week of daily pills. Levels peak 4 to 8 hours after a dose. About 77% of a dose is absorbed, and food lowers that only a little. | About 7 days, like the shots, so daily pills build to a steady level over 4 to 5 weeks. Levels peak about an hour after each tablet. |
| Studied for |
|
|
| Reported side effects |
|
|
| Sources |
|
|
